ATE423842T1 - Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung - Google Patents

Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung

Info

Publication number
ATE423842T1
ATE423842T1 AT05785460T AT05785460T ATE423842T1 AT E423842 T1 ATE423842 T1 AT E423842T1 AT 05785460 T AT05785460 T AT 05785460T AT 05785460 T AT05785460 T AT 05785460T AT E423842 T1 ATE423842 T1 AT E423842T1
Authority
AT
Austria
Prior art keywords
cells
sup
isolation
endothelial
prodensor
Prior art date
Application number
AT05785460T
Other languages
English (en)
Inventor
Eliane Popa
Martin Harmsen
Der Strate Barry Van
Luyn Marja Van
Marc Hendricks
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Application granted granted Critical
Publication of ATE423842T1 publication Critical patent/ATE423842T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05785460T 2004-08-13 2005-08-11 Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung ATE423842T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60118804P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
ATE423842T1 true ATE423842T1 (de) 2009-03-15

Family

ID=35447988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05785460T ATE423842T1 (de) 2004-08-13 2005-08-11 Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung

Country Status (7)

Country Link
US (1) US20060035290A1 (de)
EP (1) EP1776453B1 (de)
JP (1) JP2008509678A (de)
AT (1) ATE423842T1 (de)
CA (1) CA2574186A1 (de)
DE (1) DE602005012962D1 (de)
WO (1) WO2006020954A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537220A (en) * 2002-05-16 2008-06-30 Absorber Ab Method of isolating an endothelial cell and method of donor specific crossmatching
US20070014784A1 (en) * 2005-06-23 2007-01-18 Medtronic Vascular, Inc. Methods and Systems for Treating Injured Cardiac Tissue
US20070172472A1 (en) * 2005-06-23 2007-07-26 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
US20070093748A1 (en) * 2005-06-23 2007-04-26 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
EP2068897A1 (de) * 2006-10-03 2009-06-17 Medtronic, Inc. Endothel-vorläuferzellzusammensetzungen und neovaskularisation
WO2008089226A2 (en) * 2007-01-16 2008-07-24 Mayo Foundation For Medical Education And Research Assessing mammals for vascular diseases
NL2010222C2 (en) 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
WO2015066076A1 (en) * 2013-10-28 2015-05-07 Biocardia, Inc. Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
DE102020111423B4 (de) * 2020-04-27 2022-03-03 Precision For Medicine Gmbh MYH11/NDE1 Region als epigenetischer Marker für die Identifizierung von Endothel-Vorläuferzellen (EPCs)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006792A1 (en) * 1991-10-04 1993-04-15 Scimed Life Systems, Inc. Biodegradable drug delivery vascular stent
IT1282207B1 (it) * 1995-11-20 1998-03-16 Fidia Advanced Biopolymers Srl Sistemi di coltura di cellule staminali di midollo osseo umano in matrici tridimensionali costituiti da esteri dell'acido ialuronico
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US8075880B2 (en) * 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US20030180705A1 (en) * 1997-01-24 2003-09-25 Asahi Medical Co., Ltd. Method of regenerating blood vessels
US20020051762A1 (en) * 1998-01-23 2002-05-02 Shahin Rafii Purified populations of endothelial progenitor cells
US6852533B1 (en) * 1998-01-23 2005-02-08 Cornell Research Foundation, Inc. Purified populations of stem cells
US20030125615A1 (en) * 1998-02-05 2003-07-03 Yitzhack Schwartz Homing of autologous cells to a target zone in tissue using active therapeutics or substances
EP1105463A1 (de) * 1998-08-24 2001-06-13 t. Breeders, Inc. Hemangioblasten enthaltender zellverband und dessen herstellungsverfahren
US20050271701A1 (en) * 2000-03-15 2005-12-08 Orbus Medical Technologies, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
EP2324839B1 (de) * 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulozyten-kolonie-stimulierender-faktor (g-csf) zur behandlung von herzinfarkt
ITTO20010517A1 (it) * 2001-05-31 2002-12-01 Giulio Alessandri Cellule progenitrici vascolari umane.
CA2457694A1 (en) * 2001-08-09 2003-02-20 Cornell Research Foundation, Inc. Platelet-derived growth factor protection of cardiac myocardium
US20040044403A1 (en) * 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
WO2003037400A2 (en) * 2001-10-31 2003-05-08 Ventrigraft Inc Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040071687A1 (en) * 2002-05-28 2004-04-15 Shahin Rafii Adult stem cell recruitment
US20040009158A1 (en) * 2002-07-11 2004-01-15 Washington University Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
CN1307300C (zh) * 2002-07-25 2007-03-28 斯克里普斯研究学院 造血干细胞和治疗新生血管性眼部疾病的方法
WO2005113751A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells

Also Published As

Publication number Publication date
CA2574186A1 (en) 2006-02-23
EP1776453A1 (de) 2007-04-25
WO2006020954A1 (en) 2006-02-23
JP2008509678A (ja) 2008-04-03
DE602005012962D1 (de) 2009-04-09
EP1776453B1 (de) 2009-02-25
US20060035290A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
Kim et al. Comparison of immunological characteristics of mesenchymal stem cells from the periodontal ligament, umbilical cord, and adipose tissue
Nakahara et al. Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells
Sun et al. Mesenchymal stem cells from patients with rheumatoid arthritis display impaired function in inhibiting Th17 cells
Yañez et al. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells
Braza et al. Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma
Cappellesso-Fleury et al. Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells
Tasso et al. The role of bFGF on the ability of MSC to activate endogenous regenerative mechanisms in an ectopic bone formation model
Najar et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6
Bieback et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum
Sela et al. Human embryonic stem cells exhibit increased propensity to differentiate during the G1 phase prior to phosphorylation of retinoblastoma protein
Götherström et al. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways
Ylöstalo et al. Reversible commitment to differentiation by human multipotent stromal cells in single-cell–derived colonies
Stadler et al. Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro
Li et al. CD49a regulates the function of human decidual natural killer cells
Đokić et al. Characterization and immunosuppressive properties of mesenchymal stem cells from periapical lesions
WO2005047524A3 (en) Compositions and methods for inducing cell dedifferentiation
Bertolo et al. An in vitro expansion score for tissue‐engineering applications with human bone marrow‐derived mesenchymal stem cells
DE602005012962D1 (de) Isolation der endothelvorläuferzellen-untermengen und verfahren zu ihrer verwendung
DK1720979T3 (da) Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller
Normanton et al. Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion
DiSpirito et al. Histone acetylation at the single-cell level: a marker of memory CD8+ T cell differentiation and functionality
Hatzfeld et al. A sub-population of high proliferative potential-quiescent human mesenchymal stem cells is under the reversible control of interferon α/β
WO2005033275A3 (en) Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
Tufa et al. Transient expression of GATA3 in hematopoietic stem cells facilitates helper innate lymphoid cell differentiation
Massidda et al. Mechanical rejuvenation of mesenchymal stem cells from aged patients

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties